Literature DB >> 9751218

Leukemia cells and the cytokine network.

S Moqattash1, J D Lutton.   

Abstract

The cytokine network plays an important role in the growth and differentiation of normal and leukemic cells. Stimulation of this network, which has positive and negative regulators, results in the induction or inhibition of certain hematopoietic events. A cytokine can have multiple effects on various cell types, and combinations of cytokines with each other or with other exogenous substances produce more pronounced effects than any cytokine or agent individually. The mechanisms by which cytokines affect normal and leukemic cell growth and viability may vary depending on the target cell or the cytokine(s) in question. Diseases such as leukemia may result from abnormalities in the cytokine network or their receptors. Cytokines play a major role in leukemogenesis. Normally, hematopoietic cells require certain cytokines for their viability and growth. When the viability factors are withdrawn, apoptotic cell death naturally occurs. Prevention of programmed cell death by the abnormal production of a cytokine may release the cell from normal growth control leading to malignant transformation. Disregulation of genes for hematopoietic growth factors and their receptors may be one of the events that leads to leukemogenesis through an aberrant autocrine growth mechanism. However, cytokines have been used as therapeutic agents in various ways. Differentiation therapy has been widely investigated and proven effective in certain types of cancer. Gene therapy, where the cytokine cDNA is used to reduce tumorigenicity and/or increase immunogenicity is promising. Another kind of therapy using alkylated growth factors has been under focus. This review summarizes the actions and interactions of cytokines that are related to leukemic cell viability and growth. The use of cytokines as therapeutic agents is also discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9751218     DOI: 10.3181/00379727-219-44311

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


  5 in total

Review 1.  [Tumor stem cell research - basis and challenge for diagnosis and therapy].

Authors:  Heidrun Karlic; Harald Herrmann; Axel Schulenburg; Thomas W Grunt; Sylvia Laffer; Irina Mirkina; Rainer Hubmann; Medhat Shehata; Brigitte Marian; Edgar Selzer; Michael Pfeilstöcker; Elisabeth Pittermann; Ulrich Jäger; Hubert Pehamberger; Christoph Zielinski; Peter Valent
Journal:  Wien Klin Wochenschr       Date:  2010-07-22       Impact factor: 1.704

Review 2.  The cancer stem cell: evidence for its origin as an injured autoreactive T cell.

Authors:  Peter Grandics
Journal:  Mol Cancer       Date:  2006-02-14       Impact factor: 27.401

3.  Targeting of the leukemia microenvironment by c(RGDfV) overcomes the resistance to chemotherapy in acute myeloid leukemia in biomimetic polystyrene scaffolds.

Authors:  Zhao-Hua Shen; Dong-Feng Zeng; Xiao-Yan Wang; Ying-Ying Ma; Xi Zhang; Pei-Yan Kong
Journal:  Oncol Lett       Date:  2016-08-24       Impact factor: 2.967

Review 4.  γδ T Cells for Leukemia Immunotherapy: New and Expanding Trends.

Authors:  Mateus de Souza Barros; Nilberto Dias de Araújo; Fábio Magalhães-Gama; Thaís Lohana Pereira Ribeiro; Fabíola Silva Alves Hanna; Andréa Monteiro Tarragô; Adriana Malheiro; Allyson Guimarães Costa
Journal:  Front Immunol       Date:  2021-09-22       Impact factor: 7.561

5.  Low IL-23 levels in peripheral blood and bone marrow at diagnosis of acute leukemia in children increased with the elimination of leukemic burden.

Authors:  Archontis Zampogiannis; Christina Piperi; Margarita Baka; Iliana Zoi; Athanasios G Papavassiliou; Maria Moschovi
Journal:  J Cell Mol Med       Date:  2021-07-08       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.